Enrollment complete in psoriasis trial

Can-Fite BioPharma (CANF) completes enrollment in its 300-patient double-blind placebo-controlled Phase 2/3 clinical trial to assess the safety and efficacy of the A3 adenosine receptor agonist CF101 for the treatment of moderate-to-severe plaque psoriasis. The trial will be conducted at 17 sites in the U.S., Israel and Europe.

The primary endpoint is a statistically significant improvement in the condition as defined by the Psoriasis Area Sensitivity Index (PASI) score and the Physicians' Global Assessment (PGA) score as well as various safety parameters.

Top-line results are expected in Q1 2015.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs